ArticleFrontiers in oncology2025
An enhanced YOLOv10 architecture for high-sensitivity and high-specificity lung cancer detection.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anatomical-Contextual YOLOv8-YOLOv12 Framework for Pulmonary Nodule Detection in CT: Multi-Organ Learning and Cross-Dataset Validation.Diagnostics (Basel, Switzerland) · 2026Article
- PD-YOLO: a high-precision detection network for fine-grained lung cancer and multi-scale pulmonary nodules in CT images.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer detection using computed tomography (CT) imaging is a critical task for early diagnosis and improved patient outcomes. However, accurate identification of small and low-contrast pulmonary nodules remains challenging due to variations in nodule size, shape, and complex background interference. To overcome these challenges, we propose HARM-YOLO, an enhanced object detection framework based on YOLOv10, specifically designed for lung cancer detection in CT scans. Our model incorporates a multi-dimensional receptive field feature extractor (C2f-MDR), a decoupled neck architecture (DENeck), series and parallel receptive field enhancement modules (SRFEM and PRFEM), and a background attention mechanism to strengthen multi-scale feature representation and suppress irrelevant signals. Extensive experiments on the LIDC-IDRI and LUNA16 datasets demonstrate that HARM-YOLO achieves a mean average precision (mAP@0.5) of 91.3% and sensitivity of 92.7%, outperforming state-of-the-art methods including YOLOv5, ELCT-YOLO, and MSG-YOLO by significant margins. With an optimal balance of 92.7% sensitivity and 89.7% precision, our framework effectively detects true nodules while minimizing false positives, addressing key needs for computer-aided diagnosis in clinical screening. Furthermore, compared against segmentation-based approaches such as nnUNet and Swin-UNet, HARM-YOLO maintains superior performance on small nodules (≤6 mm) and real-time inference speed suitable for large-scale lung cancer screening programs. Our results highlight the potential of this YOLOv10-based object detection system as a robust and efficient tool for enhancing early lung cancer detection and supporting clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.